Drug-induced liver injury: a summary of recent advances

Bibliography

• Reuben A, Koch DG, Lee WM. Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52(6):2065-76
   PubMed Web of Science ®Google Scholar
• Suzuki A, Andrade RJ, Bjornsson E, Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010;33(7):503-22
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Dierkhising R, Kremers WK, Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010;105(11):2396-404
   PubMed Web of Science ®Google Scholar
• Lewis JH. ‘Hy's law,’ the ‘rezulin rule,’ and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15(4):221-9
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Jerlstad P, Bergqvist A, Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005;40(9):1095-101
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernandez MC, Drug-induced liver injury: an analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 2005;129(2):512-21
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the united states. Gastroenterology 2008;135(6):1924-34, 1934.e1-4
   PubMed Web of Science ®Google Scholar
• Barritt AS IV, Lee J, Hayashi PH. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol 2010;8(7):635-7
   PubMed Web of Science ®Google Scholar
• Agarwal VK, McHutchison JG, Hoofnagle JH. Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010;8(5):463-70
   PubMed Web of Science ®Google Scholar
• Rockey DC, Seeff LB, Rochon J, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51(6):2117-26
   PubMed Web of Science ®Google Scholar
• Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46(11):1331-6
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Talwalkar J, Treeprasertsuk S, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51(6):2040-8
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Seeff LB, Andrade RJ, Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52(2):730-42
   PubMedGoogle Scholar
• Liss G, Rattan S, Lewis JH. Predicting and preventing acute drug-induced liver injury: what's new in 2010? Expert Opin Drug Metab Toxicol 2010;6(9):1047-61
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138(7):2246-59
   PubMed Web of Science ®Google Scholar
• Triantafyllou K, Vlachogiannakos J, Ladas SD. Gastrointestinal and liver side effects of drugs in elderly patients. Best Pract Res Clin Gastroenterol 2010;24(2):203-15
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Kaplowitz N, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49(6):2001-9
   PubMed Web of Science ®Google Scholar
• Lammert C, Bjornsson E, Niklasson A, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51(2):615-20
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mortensen ME, Zweig S, Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46(5):1453-63
   PubMed Web of Science ®Google Scholar
• Andrus MR, East J. Use of statins in patients with chronic hepatitis C. South Med J 2010;103(10):1018-22; quiz 1023
   PubMed Web of Science ®Google Scholar
• Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008;28(9):1021-41
   PubMed Web of Science ®Google Scholar
• Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010;105(5):978-80
   PubMed Web of Science ®Google Scholar
• Calderon RM, Cubeddu LX, Goldberg RB, Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010;85(4):349-56
   PubMed Web of Science ®Google Scholar
• Rzouq FS, Volk ML, Hatoum HH, Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010;340(2):89-93
   PubMed Web of Science ®Google Scholar
• Clayton TA, Lindon JC, Cloarec O, Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006;440(7087):1073-7
   PubMed Web of Science ®Google Scholar
• Winnike JH, Li Z, Wright FA, Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 2010;88(1):45-51
   PubMed Web of Science ®Google Scholar
• Ozer JS, Chetty R, Kenna G, Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol 2010;56(3):237-46
   PubMed Web of Science ®Google Scholar
• Llanos L, Moreu R, Ortin T, The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports. Aliment Pharmacol Ther 2010;31(12):1337-45
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-79
   PubMed Web of Science ®Google Scholar
• Andrews E, Armstrong M, Tugwood J, A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010;51(5):1656-64
   PubMed Web of Science ®Google Scholar
• Singer JB, Lewitzky S, Leroy E, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42(8):711-14
   PubMed Web of Science ®Google Scholar
• Lee SW, Chung LS, Huang HH, NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010;14(5):622-6
   PubMed Web of Science ®Google Scholar
• Wang T, Yu HT, Wang W, Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in chinese tuberculosis patients. J Int Med Res 2010;38(3):977-86
   PubMed Web of Science ®Google Scholar
• Bhadauria S, Mishra R, Kanchan R, Isoniazid-induced apoptosis in HepG2 cells: Generation of oxidative stress and bcl-2 down-regulation. Toxicol Mech Methods 2010;20(5):242-51
   PubMed Web of Science ®Google Scholar
• Yamada S, Tang M, Richardson K, Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009;10(9):1433-45
   PubMed Web of Science ®Google Scholar
• Tostmann A, Aarnoutse RE, Peters WH, Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells. Drug Chem Toxicol 2010;33(3):325-8
   PubMed Web of Science ®Google Scholar
• Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010;85(1):190-200
   PubMed Web of Science ®Google Scholar
• Ciccacci C, Borgiani P, Ceffa S, Nevirapine-induced hepatotoxicity and pharmacogenetics: A retrospective study in a population from mozambique. Pharmacogenomics 2010;11(1):23-31
   PubMed Web of Science ®Google Scholar
• Hosomi H, Akai S, Minami K, An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Toxicol In Vitro 2010;24(3):1032-8
   PubMed Web of Science ®Google Scholar
• Hsiao CJ, Younis H, Boelsterli UA. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact 2010;188(1):204-13
   PubMed Web of Science ®Google Scholar
• Robles M, Toscano E, Cotta J, Antibiotic-induced liver toxicity: Mechanisms, clinical features and causality assessment. Curr Drug Saf 2010;5(3):212-22
   PubMedGoogle Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-18
   PubMedGoogle Scholar
• Chatterjee S, Lyle N, Mandal A, GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther 2010;35(4):465-70
   PubMed Web of Science ®Google Scholar
• Adams DH, Ju C, Ramaiah SK, Mechanisms of immune-mediated liver injury. Toxicol Sci 2010;115(2):307-21
   PubMed Web of Science ®Google Scholar
• Jones DP, Lemasters JJ, Han D, Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv 2010;10(2):98-111
   PubMed Web of Science ®Google Scholar
• Srivastava A, Maggs JL, Antoine DJ, Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol 2010;196:165-94
   PubMedGoogle Scholar
• Stewart JD, Horvath R, Baruffini E, Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010;52(5):1791-6
   PubMed Web of Science ®Google Scholar
• Graham GG, Day RO, Graudins A, FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology 2010;18(2):47-55
   PubMedGoogle Scholar
• Michna E, Duh MS, Korves C, Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med 2010;11(3):369-78
   PubMed Web of Science ®Google Scholar
• Fritsch B. FDA's safe use initiative: reducing harm risk from acetaminophen. Pharm Today 2010;61
   Google Scholar
• Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm [Cited 11 January 2011]
   Google Scholar
• Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm239747.htm [Cited 11 January 2011]
   Google Scholar
• Karvellas CJ, Safinia N, Auzinger G, Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study. Liver Int 2010;30(6):826-33
   PubMed Web of Science ®Google Scholar
• Maddox JF, Amuzie CJ, Li M, Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A 2010;73(1):58-73
   PubMed Web of Science ®Google Scholar
• Getachew Y, James L, Lee WM, Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. Biochem Pharmacol 2010;79(9):1363-71
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008;48(4):1336-41
   PubMed Web of Science ®Google Scholar
• Myers RP, Shaheen AA. Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetaminophen-related hepatotoxicity. Hepatology 2009;49(4):1399-400
   PubMed Web of Science ®Google Scholar
• Khandelwal N, James LP, Sanders C, Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011;53(2):567-76
   PubMed Web of Science ®Google Scholar
• Watkins PB, Kaplowitz N, Slattery JT, Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006;296(1):87-93
   PubMed Web of Science ®Google Scholar
• Moyer AM, Fridley BL, Jenkins GD, Acetaminophen-NAPQI hepatotoxicity: a cell-line model system genome-wide association study. Toxicol Sci 2011;120(1):33-41
   PubMed Web of Science ®Google Scholar
• Sivilotti ML, Green TJ, Langmann C, Multiplying the serum aminotransferase by the acetaminophen concentration to predict toxicity following overdose. Clin Toxicol (Phila) 2010;48(8):793-9
   PubMed Web of Science ®Google Scholar
• Zyoud SH, Awang R, Sulaiman SA, Association between gastrointestinal manifestations following acetaminophen poisoning and outcome in 291 acetaminophen poisoning patients. Pharmacoepidemiol Drug Saf 2010;19(5):511-17
   PubMed Web of Science ®Google Scholar
• Martello JL, Pummer TL, Krenzelok EP. Cost minimization analysis comparing enteral N-acetylcysteine to intravenous acetylcysteine in the management of acute acetaminophen toxicity. Clin Toxicol (Phila) 2010;48(1):79-83
   PubMed Web of Science ®Google Scholar
• Singla R, Sharma SK, Mohan A, Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010;132:81-6
   PubMed Web of Science ®Google Scholar
• Warmelink I, Ten Hacken NH, van der Werf TS, Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 2010;105(3):1-9
   Web of Science ®Google Scholar
• Chien JY, Huang RM, Wang JY, Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 2010;14(5):616-21
   PubMed Web of Science ®Google Scholar
• Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010;14(11):1374-81
   PubMed Web of Science ®Google Scholar
• Sharma SK, Singla R, Sarda P, Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010;50(6):833-9
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 2010;54(7):2847-54
   PubMed Web of Science ®Google Scholar
• Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010;50(6):840-2
   PubMed Web of Science ®Google Scholar
• Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol 2010;7(10):543-56
   PubMed Web of Science ®Google Scholar
• Ichai P, Saliba F, Antoun F, Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. Liver Transpl 2010;16(10):1136-46
   PubMed Web of Science ®Google Scholar
• Baniasadi S, Eftekhari P, Tabarsi P, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010;22(10):1235-8
   PubMed Web of Science ®Google Scholar
• Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010;52(3):1143-55
   PubMed Web of Science ®Google Scholar
• Antela A, Ocampo A, Gomez R, Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study. HIV Clin Trials 2010;11(1):11-17
   PubMed Web of Science ®Google Scholar
• Chu KM, Boulle AM, Ford N, Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in south africa. PLoS One 2010;5(2)
   Web of Science ®Google Scholar
• Peters PJ, Stringer J, McConnell MS, Nevirapine-associated hepatotoxicity was not predicted by CD4 count >/=250 cells/muL among women in zambia, thailand and kenya. HIV Med 2010;11(10):650-60
   PubMed Web of Science ®Google Scholar
• Coffie PA, Tonwe-Gold B, Tanon AK, Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-plus program, abidjan, cote d'ivoire. BMC Infect Dis 2010;10:188
   PubMed Web of Science ®Google Scholar
• Okuda T, Norioka M, Shitara Y, Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition. Toxicol Appl Pharmacol 2010;248(3):242-8
   PubMed Web of Science ®Google Scholar
• Saha S, New LS, Ho HK, Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicol Lett 2010;195(2-3):135-41
   PubMed Web of Science ®Google Scholar
• Saha S, New LS, Ho HK, Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol Lett 2010;192(2):141-9
   PubMed Web of Science ®Google Scholar
• Rachek LI, Yuzefovych LV, Ledoux SP, Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 2009;240(3):348-54
   PubMed Web of Science ®Google Scholar
• Rizos CV, Elisaf MS, Mikhailidis DP, How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009;8(1):15-32
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52(1):79-104
   PubMed Web of Science ®Google Scholar
• Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. food and drug administration. N Engl J Med 2010;363(16):1489-91
   PubMed Web of Science ®Google Scholar
• Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc 2010;50(3):407-10
   Google Scholar
• Primeggia J, Lewis JH. Gone (from the physicians' desk reference) but not forgotten: Propylthiouracil-associated hepatic failure: a call for liver test monitoring. J Natl Med Assoc 2010;102(6):531-4
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010;95(7):3260-7
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132-41
   Google Scholar
• Rivkees SA. 63 years and 715 days to the “boxed warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010; pii: 658267
   Google Scholar
• Ferrucci LM, Bell BP, Dhotre KB, Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol 2010;44(2):e40-5
   PubMedGoogle Scholar
• Sharma T, Wong L, Tsai N, Hydroxycut((R)) (herbal weight loss supplement) induced hepatotoxicity: a case report and review of literature. Hawaii Med J 2010;69(8):188-90
   PubMedGoogle Scholar
• Harvey KJ. Hydroxycut hepatotoxicity. comment. Med J Aust 2010;192(11):669-70
   PubMed Web of Science ®Google Scholar
• Fong TL, Klontz KC, Canas-Coto A, Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010;105(7):1561-6
   PubMed Web of Science ®Google Scholar
• Rashid NN, Grant J. Hydroxycut hepatotoxicity. Med J Aust 2010;192(3):173-4
   PubMed Web of Science ®Google Scholar
• Guzman G, Kallwitz ER, Wojewoda C, Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Report Med 2009: 918156
   PubMedGoogle Scholar
• Mahady G, Low Dog T, Sarma ND, The causal relationship between the use of black cohosh-containing products and hepatotoxicity. Menopause 2010;17(5):1088-9; author reply 1089
   PubMed Web of Science ®Google Scholar
• Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 2010;17(2):426-40
   PubMed Web of Science ®Google Scholar
• Peevers CG, Moorghen M, Collins PL, Liver disease and cirrhosis because of khat chewing in UK somali men: a case series. Liver Int 2010;30(8):1242-3
   PubMed Web of Science ®Google Scholar
• Coton T, Simon F, Oliver M, Hepatotoxicity of khat chewing. Liver Int 2011;31(3):434
   PubMed Web of Science ®Google Scholar
• Teschke R. Kava hepatotoxicity–a clinical review. Ann Hepatol 2010;9(3):251-65
   PubMed Web of Science ®Google Scholar
• Mancini S, Amorotti E, Vecchio S, Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010;5(3):193-200
   PubMed Web of Science ®Google Scholar
• Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010;28(3):508-18
   PubMed Web of Science ®Google Scholar
• Bilgi N, Bell K, Ananthakrishnan AN, Imatinib and panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010;44(5):926-8
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003;21(12):2237-46
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Fukuoka M, Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol 2010;28(17):e273-4
   PubMed Web of Science ®Google Scholar
• Ku GY, Chopra A, Lopes Gde L. Jr. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer 2010;70(2):223-5
   PubMed Web of Science ®Google Scholar
• Adar T, Mizrahi M, Pappo O, Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010;44(1):e20-2
   PubMedGoogle Scholar
• Aliberti S, Grignani G, Allione P, An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. Am J Clin Oncol 2009;32(6):640-1
   PubMed Web of Science ®Google Scholar
• Poulin Y, Therien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg 2010;14(2):100-4
   PubMed Web of Science ®Google Scholar
• De Bus L, Depuydt P, Libbrecht L, Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol 2010;6(3):322-6
   PubMedGoogle Scholar
• Bell TL, Foster JN, Townsend ML. Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient. Pharmacotherapy 2010;30(5):539
   PubMedGoogle Scholar
• Lockwood AM, Cole S, Rabinovich M. Azithromycin-induced liver injury. Am J Health Syst Pharm 2010;67(10):810-14
   PubMed Web of Science ®Google Scholar
• Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother 2010;44(10):1655-9
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Mehta R, Musuku M, Repaglinide induced acute hepototoxicity. JNMA J Nepal Med Assoc 2009;48(174):162-4
   PubMed Web of Science ®Google Scholar
• Ishida S, Sugino M, Hosokawa T, Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol 2010;29(2):84-8
   PubMed Web of Science ®Google Scholar
• Ozsvar Z, Solymossi Z, Monostory K. Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver. Orv Hetil 2010;151(11):457-61
   PubMedGoogle Scholar
• Slim R, Ben Salem C, Hmouda H, Hepatotoxicity of alpha-methyldopa in pregnancy. J Clin Pharm Ther 2010;35(3):361-3
   PubMed Web of Science ®Google Scholar
• Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010;30(5):540
   PubMedGoogle Scholar
• Jacques J, Dickson Z, Carrier P, Severe sirolimus-induced acute hepatitis in a renal transplant recipient. Transpl Int 2010;23(9):967-70
   PubMed Web of Science ®Google Scholar
• Oto T, Okazaki M, Takata K, Calcineurin inhibitor-related cholestasis complicating lung transplantation. Ann Thorac Surg 2010;89(5):1664-5
   PubMed Web of Science ®Google Scholar
• Shiyovich A, Sztarkier I, Nesher L. Toxic hepatitis induced by gymnema sylvestre, a natural remedy for type 2 diabetes mellitus. Am J Med Sci 2010;340(6):514-17
   PubMed Web of Science ®Google Scholar
• Yang HN, Kim DJ, Kim YM, Aloe-induced toxic hepatitis. J Korean Med Sci 2010;25(3):492-5
   PubMed Web of Science ®Google Scholar